Invivyd, Inc. (IVVD)
IVVD moved a median of -0.52% 30 minutes after news, and -0.95% by the close. How IVVD actually reacts to news — the realized, point-in-time move the market made, measured across 338 labeled events over the last three years with zero look-ahead.
IVVD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.01% | 46% | 335 |
| 30-min | -0.52% | 42% | 337 |
| 60-min | -0.44% | 45% | 338 |
| to close | -0.95% | 40% | 331 |
| Middle 50% of IVVD reactions | -2.98% to +2.02% |
|---|---|
| Median reaction (30-min) | -0.52% |
| Measured reactions | 338 |
Half of all Invivyd, Inc. news events land between -2.98% and +2.02% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IVVD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 12 | +0.01% | 50% | -0.04% |
| Rating reiterations | 77 | -0.38% | 39% | -1.21% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how IVVD ranks against every other measured name →
That’s how IVVD usually reacts — get an email when it moves on news →Email me when IVVD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IVVD's baseline. Nothing else.
Recent IVVD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome | Press release | GlobeNewswire | -6.13% | -5.03% | |
| Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.81% | +2.34% | |
| Form 8-K Invivyd, Inc. For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -3.38% | -7.69% | |
| Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 | Press release | GlobeNewswire | -3.38% | -7.69% | |
| Invivyd to Participate in Upcoming September Investor Conferences | Press release | GlobeNewswire | -1.30% | -2.73% | |
| Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.42% | +0.05% | |
| Form 8-K Invivyd, Inc. For: Aug 30 | SEC filing · Form 8-K | SEC EDGAR | -1.16% | +2.31% | |
| Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY | Press release | GlobeNewswire | -1.16% | +2.31% | |
| Form 10-Q Invivyd, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.45% | +4.48% | |
| Form 8-K Invivyd, Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -2.45% | +4.48% | |
| Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | -2.45% | +4.48% | |
| Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +5.07% | +3.82% | |
| Form 8-K Invivyd, Inc. For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | -1.80% | -0.23% | |
| Form 8-K Invivyd, Inc. For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | -1.40% | -4.92% | |
| Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA | Press release | GlobeNewswire | -1.40% | -4.92% | |
| Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.63% | +6.48% | |
| Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine | Press release | GlobeNewswire | +0.13% | +1.92% | |
| Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administrat | Press release | GlobeNewswire | +0.48% | -3.88% | |
| Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.44% | -2.65% | |
| Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID | Press release | GlobeNewswire | +1.40% | +7.02% | |
| Invivyd to Participate in Upcoming Investor Events | Press release | GlobeNewswire | +1.34% | +0.89% | |
| Form 8-K Invivyd, Inc. For: May 19 | SEC filing · Form 8-K | SEC EDGAR | -0.48% | +3.81% | |
| Form 10-Q Invivyd, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.70% | -12.12% | |
| Form 8-K Invivyd, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -3.70% | -12.12% | |
| Form S-8 Invivyd, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.43% | +4.31% | |
| Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | -3.70% | -12.12% | |
| Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination | Press release | GlobeNewswire | +0.70% | +0.00% | |
| Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026 | Press release | GlobeNewswire | -0.33% | -4.67% | |
| Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.33% | -7.33% | |
| Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit | Press release | GlobeNewswire | -0.86% | -3.45% | |
| Form 8-K Invivyd, Inc. For: Apr 09 | SEC filing · Form 8-K | SEC EDGAR | +4.68% | +28.06% | |
| Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles | Press release | GlobeNewswire | +4.68% | +28.06% | |
| Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health | Press release | GlobeNewswire | +0.40% | +2.38% | |
| Form ARS Invivyd, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.92% | -0.77% | |
| Form DEF 14A Invivyd, Inc. For: May 19 | SEC filing · Form DEF | SEC EDGAR | -1.92% | -0.77% | |
| Form DEFA14A Invivyd, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -1.92% | -0.77% | |
| Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.85% | +0.00% | |
| Invivyd Announces Presentation at the World Vaccine Congress Washington | Press release | GlobeNewswire | +4.47% | +5.69% | |
| Form 10-K Invivyd, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -7.96% | -1.14% | |
| Form 8-K Invivyd, Inc. For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -7.96% | -1.14% | |
| Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer | Press release | GlobeNewswire | -7.96% | -1.14% | |
| Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates | Press release | GlobeNewswire | -7.96% | -1.14% | |
| Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.20% | -2.99% | |
| Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 | Press release | GlobeNewswire | +1.20% | -2.99% | |
| New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies | Press release | GlobeNewswire | -0.31% | +3.68% | |
| Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration | Press release | GlobeNewswire | -1.36% | +2.17% | |
| Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention | Press release | GlobeNewswire | +1.36% | +0.46% | |
| Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 | Press release | GlobeNewswire | +0.42% | -5.08% | |
| Form 8-K Invivyd, Inc. For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -1.59% | -0.40% | |
| Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights | Press release | GlobeNewswire | -1.59% | -0.40% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IVVD section they belong to.
Where else IVVD is measured.
IVVD earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Invivyd, Inc.'s median reaction calculated?
Every labeled IVVD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 338 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of IVVD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IVVD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.